Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Goldman Sachs Downgrades Kinder Morgan to Sell

Goldman Sachs analyst Michael Lapides downgrades Kinder Morgan (NYSE:KMI) from Neutral to Sell.

byBenzinga Newsdesk

June 14, 2021

1 minute read

Goldman Sachs analyst Michael Lapides downgrades Kinder Morgan (NYSE:KMI) from Neutral to Sell.

News

Potbelly Corporation Plans Expansion In New York City With Development Agreement And First Refranchise Deal

By Happy Mohamed

March 13, 8:10 AM

Potbelly Corporation (NASDAQ:PBPB) ("Potbelly" or the "Company"), the iconic neighborhood sandwich shop, today announced it has finalized a multi-unit development agreement along with its first

PBPB

B. Riley Securities Maintains Buy on WideOpenWest, Lowers Price Target to $19

By Benzinga Newsdesk

October 14, 8:12 AM

B. Riley Securities analyst Daniel Day maintains WideOpenWest (NYSE:WOW) with a Buy and lowers the price target from $25 to $19.

WOW

Notable Natera Insider Trades $3M In Company Stock

By Benzinga Insights

September 30, 11:07 AM

Burkes Michael Brophy, Chief Financial Officer at Natera (NASDAQ:NTRA), made a large buy and sell of company shares on September 28, according to a new SEC filing.

NTRA

Legal
News

VYNE Therapeutics Files For U.S. Patent Titled ‘USE OF NEUROKININ-1 ANTAGONISTS TO TREAT PRURITUS’

By Benzinga Newsdesk

June 10, 1:25 PM

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220210169848%22.PGNR.&OS=DN/20210169848&RS=DN/2021

VYNE

Goldman Sachs Downgrades Kinder Morgan to Sell

Related Posts

Potbelly Corporation Plans Expansion In New York City With Development Agreement And First Refranchise Deal

B. Riley Securities Maintains Buy on WideOpenWest, Lowers Price Target to $19

Notable Natera Insider Trades $3M In Company Stock

VYNE Therapeutics Files For U.S. Patent Titled ‘USE OF NEUROKININ-1 ANTAGONISTS TO TREAT PRURITUS’